Exhibit 99.1 Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights BBI-355 Phase 1/2 POTENTIATE clinical trial ongoing; initiated targeted therapy combinations in patients with tumors with EGFR or FGFR oncogene amplifications First patient dosed in Phase 1/2 STARMAP clinical trial of BBI-825 in patients with tumors with resistance gene amplifications Completed $100 million IPO; pro forma cash position of approximately $200 million supports both BBI-355 and BBI-825 through preli ...